Dilated Cardiomyopathy in Behcet's Disease in a Young Male Patient by Khederlou, Hamid et al.
Dilated Cardiomyopathy in Behcet′s Disease in a 
Young Male Patient
Hamid Khederlou 1,*, Samin Taheri 1, Alireza Sadeghi 2, 
Amirhossein Moghtader Mojdehi 3
1 School of Medicine, Student Research Center, Zanjan University of Medical 
Sciences, Zanjan, Iran
2 Assistant Professor, Department of Rheumatology, Zanjan University of Medical 
Sciences, Zanjan, Iran
3 Assistant Professor, Department of Infectious Disease, Zanjan University of Medi-
cal Science, Zanjan, Iran
* Corresponding author: Hamid Khederlou, School of Medicine, Student Research 
Center, Zanjan University of Medical Sciences, Zanjan, Iran. E-mail: ham_khed@
yahoo.com
Abstract
Behcet’s disease is a multi-systemic, inflammatory, and chronic disorder characterized 
by recurrent oral aphthous ulcers, genital ulcers, uveitis, and other systemic organ 
involvement. Cardiac involvement in Behcet’s disease is rare; however, it plays an 
important role in prognosis and increases mortality. The current researchers hereby have 
reported a case of Behcet′s disease with dilated cardiomyopathy. A 28-year-old male 
patient was presented with constitutional symptoms, oral and genital aphthous ulcers, 
pseudofolliculitis, tachycardia, arthritis, splenomegaly, erythrocyte sedimentation rate 
and C-reactive protein elevation, and left ventricular systolic dysfunction with left 
ventricular ejection fraction of 45%. Azathioprine and prednisolone were begun for the 
patient.
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Behcet’s disease (BD) is a multi-systemic, inflammatory, 
and chronic disorder characterized by a triple-symptom 
complex of recurrent oral aphthous ulcers, genital ulcers, 
uveitis [1, 2], and other diverse spectrum of clinical man-
ifestations, including skin, joint, Central Nervous System 
(CNS), gastrointestinal, pulmonary, and cardiovascular sys-
tem involvement, which are reported in addition to the ma-
jor findings of this disorder. Cardiac involvement in BD is 
known as cardio-Behcet’s disease that occurs in 7% to 31% 
of patients with BD, with a mortality rate of 20% [3]. Cardi-
ac manifestations in BD include endocarditis, myocarditis, 
pericarditis, intracardiac thrombus, endomyocardial fibro-
sis, coronary arterial disease, cardiomyopathy, myocardial 
infarction, valvular disease, diastolic dysfunction, ventric-
ular arrhythmias, and sudden cardiac death [4]. Cardio-
vascular involvement is rare, yet life-threatening, and early 
diagnosis has important therapeutic implications [5, 6]. 
Sporadic cases of cardiovascular involvement like Cardio-
myopathy (CM) have been reported. Degenerative changes 
and lysis of myocytes with cytoplasmic vacuolization, inter-
stitial focal fibrinoid deposition, and fibroblast proliferation 
could be seen in CM due to BD [7, 8]. Although sub-endo-
cardial longitudinal fibers will be the first affected region in 
patients with BD, BD could effect any of the 3 layers of the 
heart or all of them at the same time [9]. Furthermore, CM 
in BD could be ischemic, non-ischemic, or inflammatory. It 
could manifest as systolic or diastolic heart failure, or even 
as asymptomatic systolic or diastolic dysfunction [10]. The 
clinical presentation of CM in BD could include fever, dys-
pnea, chest pain, hemoptysis, and edema [11]. The aim of 
this study was to report dilated cardiomyopathy in Behcet’s 
disease in a young male patient.
CASE PRESENTATION
General Description
A 28-year-old male patient was admitted with fever, night 
sweats, anorexia, weight loss, pain, and swelling in the left 
knee. On examination, his body temperature, heart rate, 
and blood pressure were 38.4°C, 154 bit/Min, and 96/63 
mmHg, respectively. The chest, heart, and abdomen exam-
inations showed no abnormal findings. He had no lymph-
adenopathy. His left knee was tender and swollen. His 
clinical examination did not reveal any evidence of extrain-
testinal manifestation of inflammatory bowel disease. He 
had smoked 2 packs of cigarettes/day for 4 years. According 
to these presentations, the patient was worked up for Fever 
of Unknown Origin (FUO).On the third day of hospitaliza-
tion, oral aphthous ulcers and pseudofolliculitis in the an-
terior of the thigh were found. The next day, genital ulcers 
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appeared on the scrotum (Fig 1a, b, c). The patient reported 
recurrent oral and genital ulcers for the previous months. 
According to new findings on examination, rheumatologic 
consult was asked for the patient. Imaging and laboratory 
investigations results were as follows.
Figure 1: Oral Aphthous Ulcers (a), Genital Ulcers on the Scrotum 
(b) and Pseudofolliculitis in the Anterior of Thigh (c) were found 
on Examination.
Laboratory Investigations
The initial Complete Blood Count (CBC) revealed a he-
moglobin count of 11.8 g/dL, a platelet count of 308×103/
µL, and a white cell count of 11.4×103/µL. The Erythrocyte 
Sedimentation Rate (ESR) and C - reactive protein (CRP) 
were elevated to 63 mm/hr and 126 mg/l, respectively. Co-
agulation screening tests, coagulation factors, and anticoag-
ulation levels were within the normal range. Complement 
components, levels of IgA, IgG, and IgM were also normal. 
The results of his autoimmune screening tests, including peri-
nuclear-Anti-Neutrophil Cytoplasmic Antibodies (p-AN-
CA), cytoplasmic-Anti-Neutrophil Cytoplasmic Antibodies 
(c-ANCA), Human Leukocyte Antigen-B27 (HLA-B27), 
Fluorescent Antinuclear Antibody (FANA), Antinuclear An-
tibody (ANA), anti ds_DNA and anti-Citrullinated Peptide 
Antibodies (Anti-CCP) were negative. His HLA-B51 was 
negative. The anticardiolipin antibodies, antiphospholipid 
antibodies, and lupus anticoagulant were negative. Brucello-
sis tests and Tuberculin Skin Test (TST) were negative. His 
serum troponin level was within the normal range. It is im-
portant to note that his pathergy test result was also negative. 
Analysis of left knee arthrocentesis showed inflammation. 
Blood culture (×2) showed no growth.
Imaging
Ultrasound of the left knee showed effusion. Abdominal 
ultrasound detected splenomegaly with span of 157 mm. 
Whole body bone scan by Tc99m_MDP found bony lesion 
in the left knee. Serial electrocardiography along hospital-
ization showed normal sinus rhythm with sinus tachycar-
dia. Echocardiographic diameters were measured as trans-
thoracic, which reported Left Ventricular (LV) enlargement 
with diameter of 62 mm, mild Mitral valve Regurgitation 
(MR), and mild LV systolic dysfunction with Left Ventric-
ular Ejection Fraction (LVEF) of 45%. Transesophageal 
Echocardiography (TEE) reported no vegetation, no Aor-
tic Insufficiency (AI), trivial mitral valve regurgitation and 
Tricuspid valve Regurgitation (TR) and mild LV systolic 
dysfunction with LVEF of 45%. Chest X-Ray (CXR), spiral 
Computed Tomography (CT) of the lung, carotid artery 
ultrasound was evaluated by B-mode, brain CT, brain Mag-
netic Resonance Imaging (MRI) were reported as normal. 
Doppler ultrasound exam of upper and lower extremity ar-
terial and venous regions were normal. Pathological find-
ings were not found on gastrointestinal endoscopy.
Diagnosis and Treatment
Behcet’s disease was confirmed on the basis of recurrent oral 
and genital ulcers, pseudofolliculitis, monoarthritis, cardio-
vascular involvement, and no evidence of other inflammatory 
disease. Azathioprine 150 mg/d and prednisolone 60 mg/d 
were started for the patient and according to cardiac findings, 
captopril, Metoral, and carvedilol were begun. He is current-
ly being followed up.
DISCUSSION
The authors hereby have reported a case of BD with dilated 
cardiomyopathy. He was presented with fever, night sweats, 
anorexia and weight loss, pain, and swelling in the left knee. 
Oral and genital aphthous ulcers, pseudofolliculitis, tachy-
cardia, arthritis, splenomegaly, Erythrocyte Sedimentation 
Rate (ESR) and C - reactive protein (CRP) elevation, Left 
Ventricle (LV) enlargement with diameter of 62 mm and LV 
systolic dysfunction with LVEF of 45% were found in the 
evaluation. The patient fulfilled the international criteria for 
BD [7, 12] with oral and genital aphthous ulcers, pseudofol-
liculitis, along with arthritis and cardiovascular involvement, 
while an alternative diagnosis was absent.
Epidemiology
Behcet’s disease is thought to be more common along the an-
cient Silk Road, extending from Asia to the Mediterranean 
[13]. The highest prevalence of BD was seen in Turkey, with 
420 cases per 100 000 individuals. The prevalence of BD in 
Japan, Korea, China, Iran, and Saudi Arabia is also high [14].
Gender
As the current case was male, BD was more common in males 
in the Middle East, with a male-to-female ratio of 2:1. De-
spite the variability of the reported gender ratios, the disease 
tends to run a more severe course in males [15].
Age
As in the case of this study, BD is usually seen in patients in 
the late third and early fourth decades of life. However, it is 
rarely seen in childhood years, before school age, and in pe-
diatric patients [16].
Pathophysiology
Affected lesions of BD demonstrate microscopic evidence 
of inflammatory tissue infiltration with both T cells and 
neutrophils [7, 17]. Results of recent Genome-Wide Asso-
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ciation Studies (GWASs) confirm the association of BD with 
HLA-B51, IL-10, and IL23/17 [18].
Etiology
The etiology of BD is unknown. However, it may be triggered 
by a cross-reactive autoimmune response, cytokines, smok-
ing, viral, and bacterial factors; also, a familial aggregation 
is well-known meaning that carriers of HLA-B51/HLA-B5 
have an increased risk of developing BD [19, 20]. The case in 
this study reported that his father had died at middle age due 
to BD and cardiomyopathy.
History and Physical findings
History and physical findings including oral and genital 
ulcerations, uveitis, erythema nodosum, pseudofolliculitis 
rash and mono-arthritis or poly-arthritis occur in at least 
50% of patients; also, CNS involvement, such as meningi-
tis, encephalitis, and focal neurological deficits occur in as 
many as 25% of patients. Cardiac involvement includes any 
of the 3 layers of the heart involvement and coronary artery 
disease, and cardiac valves may develop vegetations with 
subsequent emboli. Vascular involvement includes migra-
tory superficial thrombophlebitis, deep venous thrombosis 
in veins, arteritis and aneurysm formation, which may in-
volve the aorta or its branches. The pathergy test is helpful 
but is not sensitive or specific for the diagnosis of BD [21, 
22].
Treatment
Treatment of BD must be appropriate to the individual 
patient, severity of disease, and major organ involvement. 
Corticosteroids are useful in controlling acute manifesta-
tions. Colchicine has also been used to prevent mucocu-
taneous relapse [23]. For severe mucocutaneous lesions, 
systemic corticosteroids, azathioprine, pentoxifylline, 
dapsone, interferon-alfa, colchicine, and thalidomide have 
demonstrat TNF-α blockers, cyclosporine A, interferon-al-
fa, cyclophosphamide, rituximab, alemtuzumab, and golim-
umab [24-26].
ACKNOwLEDGEMENTS
The authors would also extend their gratitude to Dr Morteza 




1. Alpsoy E. Behcet’s disease: A comprehensive review with a focus 
on epidemiology, etiology and clinical features, and management 
of mucocutaneous lesions. J Dermatol. 2016;43(6):620-32. DOI: 
10.1111/1346-8138.13381 PMID: 27075942
2. Butt SU, McNeil J. Complete heart block in a Caucasian woman 
with Behcet’s disease: a case report. J Med Case Rep. 2016;10:102. 
DOI: 10.1186/s13256-016-0890-y PMID: 27095010
3. Hong SN, Park JC, Yoon NS, Lee SR, Kim KH, Hong YJ, et al. Ca-
rotid artery intima-media thickness in Behcet’s disease patients 
without significant cardiovascular involvement. Korean J Intern 
Med. 2008;23(2):87-93. PMID: 18646511
4. Sezen Y, Buyukhatipoglu H, Kucukdurmaz Z, Geyik R. Car-
diovascular involvement in Behcet’s disease. Clin Rheumatol. 
2010;29(1):7-12. DOI: 10.1007/s10067-009-1302-0 PMID: 
19830382
5. Farouk H. Behcet’s disease, echocardiographers, and cardiac sur-
geons: together is better. Echocardiography. 2014;31(6):783-7. 
DOI: 10.1111/echo.12524 PMID: 25041047
6. Leonardo NM, McNeil J. Behcet’s Disease: Is There Geograph-
ical Variation? A Review Far from the Silk Road. Int J Rheuma-
tol. 2015;2015:945262. DOI: 10.1155/2015/945262 PMID: 
26798344
7. Al Izzi M, El Bur M, Arif M. A diagnosis not to be missed: Behcet’s 
disease as a cause of dilated cardiomyopathy in a young Arab male 
patient. Int J Rheum Dis. 2010;13(1):97-9. DOI: 10.1111/j.1756-
185X.2009.01451.x PMID: 20374394
8. Cocco G, Gasparyan AY. Behcet’s Disease: an Insight from a Car-
diologist’s Point of View. Open Cardiovasc Med J. 2010;4:63-70. 
DOI: 10.2174/1874192401004020063 PMID: 20360978
9. Yagmur J, Sener S, Acikgoz N, Cansel M, Ermis N, Karincaoglu Y, 
et al. Subclinical left ventricular dysfunction in Behcet’s disease as-
sessed by two-dimensional speckle tracking echocardiography. Eur 
J Echocardiogr. 2011;12(7):536-41. DOI: 10.1093/ejechocard/
jer088 PMID: 21676963
10. Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifesta-
tions in Behcet’s disease. Intractable Rare Dis Res. 2015;4(2):70-5. 
DOI: 10.5582/irdr.2015.01007 PMID: 25984424
11. Leibowitz D, Korem M, Livovsky DM, Peleg H, Chajek-Shaul 
T, Hiller N. Intracardiac mass as initial cardiac manifestation 
of Behcet’s disease: think before you cut. Echocardiography. 
2014;31(8):E243-6. DOI: 10.1111/echo.12653 PMID: 24931010
12. Lee SS, Yoon HJ, Chang HK, Park KS. Fibromyalgia in Behcet’s 
disease is associated with anxiety and depression, and not with 
disease activity. Clin Exp Rheumatol. 2005;23(4 Suppl 38):S15-9. 
PMID: 16273759
13. Marzban M, Mandegar MH, Karimi A, Abbasi K, Movahedi N, 
Navabi MA, et al. Cardiac and great vessel involvement in “Behcet’s 
disease”. J Card Surg. 2008;23(6):765-8. DOI: 10.1111/j.1540-
8191.2008.00607.x PMID: 19017008
14. Krause I, Yankevich A, Fraser A, Rosner I, Mader R, Zisman D, et 
al. Prevalence and clinical aspects of Behcet’s disease in the north 
of Israel. Clin Rheumatol. 2007;26(4):555-60. DOI: 10.1007/
s10067-006-0349-4 PMID: 16897122
15. Heper G, Polat M, Yetkin E, Senen K. Cardiac findings in Behcet’s 
patients. Int J Dermatol. 2010;49(5):574-8. DOI: 10.1111/j.1365-
4632.2010.04424.x PMID: 20534096
16. Direskeneli H, Eksioglu-Demiralp E, Yavuz S, Ergun T, Shinnick T, 
Lehner T, et al. T cell responses to 60/65 kDa heat shock protein 
derived peptides in Turkish patients with Behcet’s disease. J Rheu-
matol. 2000;27(3):708-13. PMID: 10743813
17. Ozen S, Eroglu FK. Pediatric-onset Behcet disease. Curr Opin Rheu-
matol. 2013;25(5):636-42. DOI: 10.1097/BOR.0b013e328363e-
a8b PMID: 23872902
18. Ulusan Z, Karadag AS, Tasar M, Kalender M, Darcin OT. Behcet’s 
disease and cardiovascular involvement: our experience of as-
ymptomatic Behcet’s patients. Cardiovasc J Afr. 2014;25(2):63-6. 
DOI: 10.5830/CVJA-2014-003 PMID: 24844550
19. Baharav E, Weinberger A. The HLA-B*5101 molecule-binding 
capacity to antigens used in animal models of Behcet’s disease: a 
bioinformatics study. Isr Med Assoc J. 2012;14(7):424-8. PMID: 
22953618
20. Hamzaoui K, Berraies A, Kaabachi W, Ammar J, Hamzaoui A. 
Pulmonary manifestations in Behcet disease: impaired natural 
killer cells activity. Multidiscip Respir Med. 2013;8(1):29. DOI: 
10.1186/2049-6958-8-29 PMID: 23556512
21. Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions 
of Behcet’s disease. Yonsei Med J. 2007;48(4):573-85. DOI: 
10.3349/ymj.2007.48.4.573 PMID: 17722228
22. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler 
S, Zeiher AM. Elevated C-reactive protein levels and impaired en-
dothelial vasoreactivity in patients with coronary artery disease. 
Circulation. 2000;102(9):1000-6. PMID: 10961964
23. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul 
A, et al. EULAR recommendations for the management of Behcet 




International Journal of Cardiovascular Practice 
24. Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management 
of Behcet’s disease. Ther Clin Risk Manag. 2015;11:611-9. DOI: 
10.2147/TCRM.S56163 PMID: 25926738
25. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda 
O, et al. Efficacy of anti-TNF alpha in severe and/or refractory 
Behcet’s disease: Multicenter study of 124 patients. J Autoim-
mun. 2015;62:67-74. DOI: 10.1016/j.jaut.2015.06.005 PMID: 
26162757
26. Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, 
Mat C, et al. Apremilast for Behcet’s syndrome--a phase 2, place-
bo-controlled study. N Engl J Med. 2015;372(16):1510-8. DOI: 
10.1056/NEJMoa1408684 PMID: 25875256
